Impending Advances in Sustained Anti-VEGF Delivery for Neovascular Retinal Diseases: An Up-Close Look!


Impending Advances in Sustained Anti-VEGF Delivery for Neovascular Retinal Diseases: An Up-Close Look!


Release Date: December 30, 2020 
Last Reviewed: December 12, 2020
Expiration Date: December 30, 2021
Time to Complete Activity: 1.5 hours

Faculty Co-Chairs
Nancy M. Holekamp, MD
Director, Retinal Services 
Pepose Vision Institute 
Chesterfield, MO 

Carl D. Regillo, MD, FACS
Director, the Retina Service of Wills Eye Hospital 
Professor of Ophthalmology
Thomas Jefferson University
Partner, Mid Atlantic Retina 
Philadelphia, PA 

This activity is provided by Paradigm Medical Communications, LLC. 

This activity is jointly provided by Global Education Group and Paradigm Medical Communications, LLC in partnership with Salus University Pennsylvania College of Optometry for COPE credit.

                                                                                              

Disclosure of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Target Audience
This activity is designed to meet the educational needs of comprehensive ophthalmologists. It may also benefit retina specialists, optometrists, and other clinicians involved in the care of patients with neovascular retinal diseases.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify anti-VEGF treatment strategies that are associated with improved visual acuity and anatomical outcomes, and that arrest disease progression 
  • Evaluate clinical trial designs, safety, and efficacy for emerging strategies under investigation for sustained delivery of anti-VEGF agents used to treat neovascular retinal diseases
  • Recognize aspects of surgical implantation and/or refill of novel anti-VEGF delivery strategies that are important to patient education
Agenda
  • The Unmet Need for Durable Treatment of Neovascular Retinal Diseases
  • Anti-VEGF for Treatment of Neovascular Retinal Diseases
  • Reducing Anti-VEGF Treatment Burden: The Promise of Sustained Delivery
  • New Modes of Anti-VEGF Delivery: What Do Our Patients Need to Know?
  • Q&A
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians

Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Optometrist Continuing Education
This activity, COPE Activity Number 120930, is accredited by COPE for continuing education for optometrists.

COPE Course ID: 70764-PS
COPE Activity ID: 120930

Please consult your state’s Board of Optometry to determine if the CE credit may apply toward your CE requirement for license renewal.

PA Continuing Education
PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. 

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.  Individuals are responsible for checking with the AANPCP for further guidelines.

Instructions for Participation 
To receive a CME certificate of participation, you should:
  • Follow instructions to register or log in with your professional information and complete the pre-activity assessment
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949 or cme@paradigmmc.com.

There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF Documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader.

Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.

Disclosures
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below. Any potential conflicts of interest have been resolved.

Faculty 

Nancy M. Holekamp, MD
Consulting Fees: Acucela Inc; Allergan, Inc; Apellis Pharmaceuticals; Bayer Corporation; Clearside Biomedical; Gemini Therapeutics, Inc; Genentech, Inc; Gyroscope Therapeutics Limited; Katalyst Surgical; Lineage Cell Therapeutics, Inc; Nacuity Pharmaceuticals, Inc; Notal Vision, Inc; Novartis; Polyactiva Pty Ltd; Regeneron Pharmaceuticals, Inc 
Grant/Research Support: Gemini Therapeutics, Inc; Genentech, Inc; Gyroscope Therapeutics
Patents/Intellectual Property Rights: Katalyst Surgical
Speaker’s Bureau: Allergan, Inc; Genentech, Inc; Novartis; Regeneron Pharmaceuticals, Inc; Spark Therapeutics
Stockholder: Katalyst Surgical

Carl D. Regillo, MD, FACS
Consulting Fees: Adverum Biotechnologies, Inc; Allergan, Inc; Chengdu Kanghong Pharmaceutical Group Co, Ltd; Eyepoint Pharmaceuticals; Genentech, Inc; Graybug Vision, Inc; IVERIC Bio, Inc; Kodiak Sciences Inc; Novartis
Grant/Research Support: Adverum Biotechnologies, Inc; Allergan, Inc; Apellis Pharmaceuticals; Chengdu Kanghong Pharmaceutical Group Co, Ltd; Eyepoint Pharmaceuticals; Genentech, Inc; Graybug Vision, Inc; IVERIC Bio, Inc; Kodiak Sciences, Inc; Novartis; Regeneron Pharmaceuticals, Inc; REGENXBIO Inc

Sunir J. Garg, MD (independent peer reviewer):
Consulting Fees: Allergan, Inc; Apellis Pharmaceuticals; Bausch & Lomb; Boehringer Ingelheim Pharmaceuticals, Inc; Johnson & Johnson Services, Inc; Kanaph Therapeutics Inc
Grant/Research Support: Aerpio Pharmaceuticals; Apellis Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Regeneron Pharmaceuticals, Inc

Independent resident reviewer has no financial relationships to disclose.

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.


Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.


Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC, accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website"). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us

If you have any questions or comments, please email us at contactus@paradigmmc.com

© 2020 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.